Side-by-side comparison of AI visibility scores, market position, and capabilities
Ophthalmic robotics company raised $125M Series B in Jun 2025; first human cataract trials launching 2026;
ForSight Robotics is developing the Oryom — a surgical robot designed to reach any anatomical point within the human eye, enabling robotic cataract surgery, retinal procedures, and glaucoma interventions with precision exceeding human capability. The company raised $125 million in Series B financing in June 2025 and is launching its first human cataract trials in 2026, making it one of the most clinically advanced ophthalmic robotics companies globally. If the 2026 trial results are positive, an FDA submission pathway follows for the world's first robotic eye surgery system at clinical scale.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.